Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Olema Pharmaceuticals ( (OLMA) ) has issued an announcement.
Olema Pharmaceuticals has forged a significant collaboration with Novartis to advance its pivotal Phase 3 OPERA-02 trial, combining palazestrant with ribociclib for treating frontline ER+/HER2- metastatic breast cancer. Concurrently, Olema secured a $250 million private placement to fuel its clinical endeavors, including the ongoing OPERA-01 and new trials, positioning it well for future milestones. This strategic partnership and financial boost underscore Olema’s commitment to transformative cancer therapies, appealing to investors keen on innovative biopharma initiatives.
For an in-depth examination of OLMA stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- ‘Time to Jump Ship,’ Says Investor About MicroStrategy Stock
- Nvidia and Microsoft: Why This Top Investment Firm Decided to Dump Shares
- Wells Fargo (NYSE:WFC) Departs Philadelphia Sports Arena
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
